Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons

Ann N Y Acad Sci. 1996 Dec 26:805:270-7; discussion 277-9. doi: 10.1111/j.1749-6632.1996.tb17489.x.

Abstract

PACAP is a member of the secretin/glucagon/VIP family of peptides and demonstrates neurotrophic and neuroprotective effects at very low concentrations. We have previously shown that PACAP crosses the BBB to a modest degree by way of a saturable transport system. PACAP is transported across the BBB as an intact peptide to enter the parenchymal space of the brain. We tested the possibility that this modest rate of transport would be sufficient to produce the low levels of PACAP needed in the brain to exert a neuroprotective effect against ischemia. We found that PACAP given intravenously could indeed prevent the death of CA1 hippocampal neurons, even if the administration of PACAP was delayed for 24 h after the ischemic event. We suggest that iv PACAP could be neuroprotective after stroke, cardiac arrest, and hypotensive episodes.

Publication types

  • Review

MeSH terms

  • Animals
  • Blood-Brain Barrier*
  • Brain / metabolism
  • Cell Death / drug effects
  • Hippocampus / cytology
  • Hippocampus / drug effects
  • Hippocampus / pathology*
  • Ischemic Attack, Transient / pathology
  • Ischemic Attack, Transient / physiopathology*
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / pathology*
  • Neuropeptides / metabolism*
  • Neuropeptides / pharmacokinetics
  • Neuropeptides / pharmacology
  • Neurotransmitter Agents / metabolism
  • Pituitary Adenylate Cyclase-Activating Polypeptide

Substances

  • Neuropeptides
  • Neurotransmitter Agents
  • Pituitary Adenylate Cyclase-Activating Polypeptide